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“ I was no longer a beingwith feelings, ideas, beliefs,points of view or a future.
All I was, was the recipient
of a specific drug and
that was it.”
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1 Choice of medicine should be negotiated between the individual and
the doctor.  It should be based on the assessment of need, the benefit
and side effect profile of each medicine and the relative importance of
these to the person’s quality of life.
2 The medicine should be reviewed regularly (at least twice a year) and
alternatives made available if the first choice is proving ineffective or
producing unwanted side effects.
3 Where discussion between the individual and the doctor is not possible
or in cases of doubt, atypical antipsychotics should be preferred
because of their lower risk of Extra Pyramidal Side Effects and Tardive
Dyskinesia.
4 Where typical antipsychotics are used, doses should be kept at the
lowest therapeutic dose and frequent monitoring for all side-effects
should be conducted.
5 Where  an individual has not responded to typical or atypical medicine
clozapine should be prescribed.
6 When a change in medicine takes place doctors should ensure that
appropriate support is available to assist people with the change.
7 Atypical antipsychotics should be the first-line default medicine
prescribed for people with symptoms of psychosis. 
“Each patient should ideally be prescribed only one antipsychotic,
preferably in a single dosage form”
The Maudsley Prescribing Guidelines 2001
At present people with schizophrenia are generally getting cheaper
medicines with poorly tolerated side-effects when better medicine is
available, and in mental healthcare .... that’s just typical.
For further findings from the research, including method and limitations 
please access the nsf website at www.nsf.org.uk/information/research/ 
This report was written by: Paul Corry, Gary Hogman and George Sandamas.
“
This report follows A Question of Choice, published in 2000.
Like the first report, which highlighted the lack of choice
offered to people, That’s Just Typical draws on findings from
the largest ever survey of people using medicines for the
treatment of severe mental illnesses. This new report narrows
the focus to people taking antipsychotics for a diagnosis of
schizophrenia. It looks at people’s experiences of using a
range of drug treatments, how well-suited they found them
and which drugs they found tolerable and intolerable.
The results are in some places shocking, in others astounding.
They clearly indicate people’s preferences for atypicals.
These two reports, and further ones to follow, offer a fresh
perspective to the reams of research that has, over many
years, undervalued the voice of the person with severe mental
illness in favour of randomised control trials. Here, the views
of people whose lives are dramatically affected by the success
or failure of a particular drug treatment are paramount. It is
their views that guide the report’s recommendations and it
should be their experiences that guide future policy.
The National Schizophrenia Fellowship, Mind and the Manic
Depression Fellowship, who have worked together on this
research, believe that decision-makers will listen to those on
the receiving end of their policies, but, more than that, urge
professionals and policy makers to fully involve people before
and during the processes.
Cliff Prior
Chief Executive, NSF
The National Institute for Clinical Excellence has been asked by government
to compare so-called “atypical” medicines for schizophrenia with older and
cheaper medicines, the so-called “typicals.” Existing research has not asked
the people who take these two types of medicine how they compare with
each other, or which of the two types of medicine is their preferred choice.
The National Schizophrenia Fellowship, the Manic Depression Fellowship
and MIND, the three largest mental health membership charities in the UK,
conducted this survey to discover the missing evidence. Around 15,000
questionnaires were distributed through NSF, MIND and MDF mailing lists.
2,663 people replied. 2,222 (85%) had direct experience of a mental illness,
while 387 (15%) were informal carers.
In addition, 10 focus groups - five with service users and five with carers - were
organised. Quotes throughout this report are drawn from these focus groups.
Over 400 different medicines were recorded by survey respondents.
The older “typical” antipsychotics were the most prescribed drugs in
our survey. They are used in the treatment of schizophrenia, severe
anxiety and the manic phase of manic-depression.1
The findings reported below are from a sub-group of the
respondents. In order to reduce the number of possibly
confounding variables, only the responses from people with a
diagnosis of schizophrenia who were in receipt of an antipsychotic
as their first medicine (525 people) were included. Of these, 34%
were women, 64% men with 2% not submitting their gender. The
average age of these respondents was 41; age range 19 to 78.
Almost all respondents classified themselves as white.
Polypharmacy, the use of a “cocktail” of medicines, may be used with
people who have more than one diagnosis, to counteract the unwanted side
effects of another medicine or enhance a specific therapeutic action. Our
study has found that over 16% of respondents with schizophrenia were on
two or more antipsychotics. People with schizophrenia who experience
side-effects from their antipsychotic medicines may be given anti-
cholinergics to counteract them. There are several problems with
polypharmacy, not least the confusion it can cause in trials designed to
identify the therapeutic benefits or side effects of a particular medicine, and
the risks of a drug interaction developing. Good practice dictates that
people should receive only one antipsychotic and, preferably, in a single
dosage form.4,5
Introduction 
& Method
Preface
“ “
Anne from London says
Too often professionals 
pigeon-hole people with mental
illness and treat them as
hopeless cases
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Table One: Demographic information
Gender
Women 1,398 (53%) Men 1,265 (47%)  
Ethnic origin
White 2,408 (91%) Other 255 (9%)  
Average age
People with a mental illness 45 Carers 51 
Age range 
People with a mental illness 16 to 98 Carers 19 to 95 
Main diagnosis
Schizophrenia 969 (37%)  Manic Depression 890 (34%)
Depression 547 (21%)  Personality Disorder 49 (2%)
Other 189 (7%)
Table Two: What medicines?
Types of First medicine All medicines
medicines recorded recorded 
Antipsychotic: Typical 614 (23%) 1266 (26%)  
Antipsychotic: Atypical 470 (18%) 646 (13%)  
Anti-Depressants 491 (18%) 1063 (22%)  
Mood Stabilisers 539 (20%) 1002 (20%)  
Anti-cholinergics 35 (1%) 350 (7%)  
Other 276 (10%) 574 (12%)  
Not Recognised/Missing 237 (9%) -
“
“
Peter, from Cardiff, says
It was only through talking 
to other service users that I
found out what medicines were
available, their relative pros 
and cons and my rights in
relation to them.
Typical medicines have been available since the 1950s. They are cheap and
come in a range of forms, including tablet and long-lasting depot injections.
Atypical medicines have been available since the 1970s, although only came
into anything like common usage in the 1990s. Take-up of the newer atypical
antipsychotics has been slow, probably due to their higher costs.2,3  Today,
they come in a range of forms including tablet, syrup, quick-dissolving “velo-
tabs” and, in the coming months, in long-lasting depot injections. A dose-by-
dose comparison shows that atypical drugs are up to 30 times as expensive
as typicals. However, when wider costs such as re-hospitalisation rates are
taken into account, cost differences are sharply reduced. 
Side Effects
The efficacy of all antipsychotics on the “positive” symptoms of
psychoses, such as hallucinations and delusions is very similar,
(clozapine, an atypical, is an exception, being effective for some
people who have not responded to other medicines). It is, therefore,
the side-effect profile of the medicines which distinguishes them.
The range and frequency of side-effects remain constant across
groups but the individual experience and intensity varies. People
have different views about which medicine and which
side-effect profile is “right” for them. When the side-effects
become intolerable the majority stop taking the medicine. 
Chart Three shows the range of side effects commonly associated with
antipsychotics broken down into typical and atypical medicines. The chart
does not measure the intensity of the side effects, nor does it measure how
debilitating they may be to each individual. However, there is no debate that
the impact of side effects on a person’s ability to recover a meaningful quality
of life is a real issue when deciding the appropriate medicine. As we report
later, there is also a question over whether the impact of side effects impedes
two-way communication and co-operation between the health professional
and the person with mental illness. 
Chart Three shows graphically that for all the commonly reported side effects -
from muscle spasms through weight gain to effects on eyes - the side effects
from atypical medicines affect fewer people. Put another way, people receiving
the older, cheaper typicals are more likely to experience side effects, in the
case of muscle spasms and muscle tremors up to four times as likely. Later,
we look at the medicines that people found “best” and “worst” in the context
of their willingness to continue taking them.
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Typical
v Atypical
Information &
Involvement
“ “Steve from Belfast, saysI was not told about the sideeffects of my medication andused to walk miles everyday
due to the intensity of the inner
restlessness that I felt.
People involved in our focus groups supporting this research
repeatedly complained that they were not being provided with
information nor were they being involved in decision making about the
medicines they were expected to take. These experiences are
supported by the survey results. But was there a marked difference in
the experiences of people in receipt of “typicals” and “atypicals”? 
The data in the question blocks refers to everyone in the sample (525).
This information is then divided by the two medicine groups in the text.
We asked:
Did your doctor (psychiatrist) talk to you about your medicine?
Yes 361 (70%)          No 157 (30%)
As Chart Four shows, there was a significant difference between the groups.
Those people receiving atypical medicines were much more likely (79%) to be
involved in discussions with professionals about their treatment than those
receiving typicals (63%). These findings are in line with other research and may
point to a lack of confidence on the part of health professionals in discussing
the particularly serious side-effects that are associated with typical medicines.
and we asked:
Did your doctor (psychiatrist) ever offer you a choice of medicine?
Yes 210(40%)          No 309(60%)
As Chart Five shows, there was again a significant difference between the
experiences of people receiving atypical medicines and those receiving typical
medicines. Although only a minority in both groups said that they had been
offered a choice, those receiving atypical medicines were the most likely to be
fully involved with 48 per cent offered a choice compared to just 35 per cent
of people receiving typicals. 
We asked:
Did you receive any written information about the possible side 
effects of the medicine you were prescribed?
Yes 261(50%)          No 260(50%)
The headline figures show that only half the people diagnosed with
schizophrenia and in receipt of either a typical or an atypical medicine are
being offered written information on side effects. However, there is a dramatic
difference when the headline figures are broken down into those receiving
atypicals and typicals. Two thirds of people receiving atypicals (68%) were
given written information about possible side effects, compared with just 37
per cent of those on typical medicines. Written information that can be taken
away and discussed with friends and family is vital when deciding what
medicine will best suit an individual. This finding supports our earlier
suggestion that many health professionals may be loathe to discuss the
particularly serious side effects that are associated with typical medicines.
Chart Three: People’s experience of side-effects by
current main medicine.
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Chart Four: Did your doctor talk to you about your
medicine? 
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Chart Five: Did your doctor ever offer you a choice of
medicine? 
100
80
60
40
20
0
P
er
ce
nt
ag
e 
%
Typicals Atypicals
Yes
No
Chart Six: Did you receive any written information
about the side-effects of the medicine?
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Confidence
in Medicines
“ “Pat from Birmingham said,I suffered in silence until I couldtake no more. In the end I
became non-compliant and
ended up in hospital. Conclusion - 
A question of
informed choice
“ “
Martin from Norwich said,
Initially I was put on 
the cheap rubbish, my weight
ballooned and I felt even worse
on the medication.
Not everyone responds in the same way to medicines. There are
individuals currently in receipt of typical antipsychotics who respond
well to them just as there are individuals in receipt of atypical
antipsychotics who react badly to them. Best practice must build on a
policy of finding, through meaningful two-way communication, the
most appropriate medicine for an individual’s current circumstances.
However, there must be a “default” setting for those people who
become ill for the first time and for those people whose ability to
make decisions on their own behalf is temporarily undermined by the
course of their illness. 
The evidence outlined here - evidence provided by the people who use these
medicines - is that atypicals are, for most people, better tolerated, associated
with fewer and less severe side effects and allow for better communication
with health professionals. There is strong evidence from this survey that
people in receipt of atypicals are more likely to experience a meaningful
relationship with health professionals and better outcomes.
New medicines are more expensive than old medicines.  But the cost of a
relapse - with inpatient stays, additional hours of medical staff and daycare -
far outweighs the difference. Taking new medicine that you are happy with is
cheaper than not taking older medicine and becoming ill.
For these reasons, atypicals should become the standard default first-line
pharmaceutical treatment for schizophrenia, delivered as part of a holistic
package of health and social care support.
It is not uncommon for people in receipt of any kind of medicine, whether
antibiotics or antipsychotics, to stop taking it at some point without or
against a doctor’s advice. The cost to services in Britain of people with a
mental illness stopping treatment in this way is estimated to be £100
million.6 Drug trials involving people with mental illness have high “drop out”
or non-compliance rates, casting doubt over the value of statistical
information derived from them. The cost to individuals cannot be quantified
in financial terms. There is a risk of relapse, admission to hospital, loss of
confidence in the ability to recover a meaningful life, a breakdown in trust
with health professionals and so on. 
We asked:
Have you ever stopped taking your medicine without the knowledge 
or support of your doctor?
Yes 191(42%) No 262(58%)
Again, there was a significant difference between those taking older typical
medicines and those people taking the newer atypical medicines. Almost
half (47%) of people receiving typical medicines had stopped taking the
medicine - “become non-compliant” in the medical jargon. Just over one-
third of people taking the atypicals (35%) had done the same. The main
reason given by people for stopping their medicine was side-effects. 
These findings would support the assumption that the sometimes severe
and disabling side effects associated with the older typical medicines led to
people simply stopping taking them. Further support for such an
assumption would be provided by asking people to draw a Top Three of
medicine “hits” and medicine “misses.”
We asked 1,084 respondents who indicated that an antipsychotic was
currently their first form of medicine:
‘Which medicine for your mental health problem was the best
you have ever had?’
‘Which medicine for your mental health problem was the 
worst you have ever had?’
The results are set out in Tables One and Two.
A very clear pattern emerges from the two Tables shown opposite. The typical
antipsychotics fill the top three worst drugs for people from both groups. The
choice of “best” medicine is no doubt limited to the medicines people have gained
access to. Therefore, those taking the older drugs named some of the brand
leaders as best, while those people taking the atypicals named brand leaders from
that category as best. However, given the limited access to and rationing of the
new atypicals, it is likely that those with access to them will have experienced the
older medicines at some time. The same cannot be said of people on the older
medicines.
Olanzapine
n=78 (15%)
Clozapine
n=60 (11%)
Risperidone
n=44 (8%)
Only those in
receipt of typical
antipsychotics
(n=614)
Depixol
n=39 (13%)
Sulpiride
n=36 (12%)
Stelazine
n=23 (8%)
Only those in
receipt of atypical
antipsychotics
(n=470)
Olanzapine
n=67 (30%)
Clozapine
n=57 (26%)
Risperidone
n=46 (21%)
Table One: Which medicine for your mental
health problem was the best you have ever had?
Table Two: Which medicine for your mental
health problem was the worst you have 
ever had?
People in receipt
of either type of
antipsychotic
(n=1084)
Chlorpromazine
n=81 (16%)
Haloperidol
n=44 (8%)
Stelazine
n=35 (7%)
Only those in
receipt of typical
antipsychotics
(n=614)
Chlorpromazine
n=46 (15%)
Haloperidol
n=23 (8%)
Stelazine
n=20 (7%)
Only those in
receipt of atypical
antipsychotics
(n=470)
Chlorpromazine
n=35 (16%)
Haloperidol
n=21 (9%)
Depixol
n=15 (7%)
People in receipt
of either type of
antipsychotic
(n=1084)
